{"id":"W2623888527","doi":"10.1016/s0140-6736(17)31279-5","title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":556,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"","keywords":"Medicine; Etanercept; Placebo; Psoriasis; Internal medicine; Psoriasis Area and Severity Index; Clinical trial; Dermatology; Physical therapy; Gastroenterology; Tumor necrosis factor alpha; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002952298,0.002207039,0.00505769,0.0006732771,0.0005251759,0.001683271,0.001230395,0.00298288,0.008362965],"category_scores_gemma":[0.002543051,0.00101139,0.004571047,0.0007033779,0.001500527,0.001826873,0.0005495921,0.004136916,0.001214566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121328,"about_ca_system_score_gemma":0.000893229,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001974267,"about_ca_topic_score_gemma":0.003526021,"domain_scores_codex":[0.9985525,0.0007140243,0.0001210707,0.0002429577,0.0001218639,0.0002475904],"domain_scores_gemma":[0.9987073,0.0005334213,0.0003447668,0.0001052263,0.00006916365,0.0002400398],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.978243,0.001596023,0.000182202,0.001460697,0.001752753,0.00002748865,0.00004317269,0.000137457,0.001570837,0.00008023709,0.0005878969,0.0143183],"study_design_scores_gemma":[0.9833188,0.01425951,0.0007757625,0.00005837783,0.0008199661,0.00001783108,0.00001625004,0.0000671153,0.0001160975,0.0001161124,0.0004241502,0.00001009337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.916015,0.06269319,0.001695547,0.002803096,0.002400426,0.005312009,0.003024982,0.0003651364,0.005690767],"genre_scores_gemma":[0.9630449,0.01922516,0.002584495,0.002842546,0.001209023,0.004089811,0.00165649,0.00007610773,0.005271465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008362965,"threshold_uncertainty_score":0.02797693,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1043647610923764,"score_gpt":0.3656328327658314,"score_spread":0.261268071673455,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}